Risedronate for prevention and treatment of osteoporosis in postmenopausal women

Robert R. Recker, Janet Barger-Lux

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Risedronate sodium is an N-containing bisphosphonate that has been approved for the prevention and treatment of osteoporosis in postmenopausal women. An increase in the rate of bone remodelling is a regular feature of oestrogen withdrawal during the menopausal transition, but excessive remodelling leads to bone fragility. Risedronate and similar compounds reduce the rate of bone remodelling by suppressing the action of osteoclasts. The antifracture efficacy of risedronate is impressive. In large clinical trials of postmenopausal women with osteoporosis-related fracture(s) at entry, the risk of incident vertebral and non-vertebral fractures was reduced by ∼ 40%. In older women at risk for hip fracture, incident hip fractures were also reduced by ∼ 40%. Antifracture efficacy develops within the first 6 months, and treatment has been followed for as long as 5 years without deleterious effects on bone. We await reports of experience with risedronate in 'real-world' cases of greater complexity (i.e., in patients with co-morbidities and medications that would have excluded them from published clinical trials.

Original languageEnglish
Pages (from-to)465-477
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Volume6
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Postmenopausal Osteoporosis
Bone Remodeling
Hip Fractures
Clinical Trials
Bone and Bones
Diphosphonates
Osteoclasts
Therapeutics
Osteoporosis
Estrogens
Morbidity
Risedronate Sodium

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Risedronate for prevention and treatment of osteoporosis in postmenopausal women. / Recker, Robert R.; Barger-Lux, Janet.

In: Expert Opinion on Pharmacotherapy, Vol. 6, No. 3, 03.2005, p. 465-477.

Research output: Contribution to journalReview article

@article{23a7ff8d10524ed58d543bae722ee41d,
title = "Risedronate for prevention and treatment of osteoporosis in postmenopausal women",
abstract = "Risedronate sodium is an N-containing bisphosphonate that has been approved for the prevention and treatment of osteoporosis in postmenopausal women. An increase in the rate of bone remodelling is a regular feature of oestrogen withdrawal during the menopausal transition, but excessive remodelling leads to bone fragility. Risedronate and similar compounds reduce the rate of bone remodelling by suppressing the action of osteoclasts. The antifracture efficacy of risedronate is impressive. In large clinical trials of postmenopausal women with osteoporosis-related fracture(s) at entry, the risk of incident vertebral and non-vertebral fractures was reduced by ∼ 40{\%}. In older women at risk for hip fracture, incident hip fractures were also reduced by ∼ 40{\%}. Antifracture efficacy develops within the first 6 months, and treatment has been followed for as long as 5 years without deleterious effects on bone. We await reports of experience with risedronate in 'real-world' cases of greater complexity (i.e., in patients with co-morbidities and medications that would have excluded them from published clinical trials.",
author = "Recker, {Robert R.} and Janet Barger-Lux",
year = "2005",
month = "3",
doi = "10.1517/14656566.6.3.465",
language = "English",
volume = "6",
pages = "465--477",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Risedronate for prevention and treatment of osteoporosis in postmenopausal women

AU - Recker, Robert R.

AU - Barger-Lux, Janet

PY - 2005/3

Y1 - 2005/3

N2 - Risedronate sodium is an N-containing bisphosphonate that has been approved for the prevention and treatment of osteoporosis in postmenopausal women. An increase in the rate of bone remodelling is a regular feature of oestrogen withdrawal during the menopausal transition, but excessive remodelling leads to bone fragility. Risedronate and similar compounds reduce the rate of bone remodelling by suppressing the action of osteoclasts. The antifracture efficacy of risedronate is impressive. In large clinical trials of postmenopausal women with osteoporosis-related fracture(s) at entry, the risk of incident vertebral and non-vertebral fractures was reduced by ∼ 40%. In older women at risk for hip fracture, incident hip fractures were also reduced by ∼ 40%. Antifracture efficacy develops within the first 6 months, and treatment has been followed for as long as 5 years without deleterious effects on bone. We await reports of experience with risedronate in 'real-world' cases of greater complexity (i.e., in patients with co-morbidities and medications that would have excluded them from published clinical trials.

AB - Risedronate sodium is an N-containing bisphosphonate that has been approved for the prevention and treatment of osteoporosis in postmenopausal women. An increase in the rate of bone remodelling is a regular feature of oestrogen withdrawal during the menopausal transition, but excessive remodelling leads to bone fragility. Risedronate and similar compounds reduce the rate of bone remodelling by suppressing the action of osteoclasts. The antifracture efficacy of risedronate is impressive. In large clinical trials of postmenopausal women with osteoporosis-related fracture(s) at entry, the risk of incident vertebral and non-vertebral fractures was reduced by ∼ 40%. In older women at risk for hip fracture, incident hip fractures were also reduced by ∼ 40%. Antifracture efficacy develops within the first 6 months, and treatment has been followed for as long as 5 years without deleterious effects on bone. We await reports of experience with risedronate in 'real-world' cases of greater complexity (i.e., in patients with co-morbidities and medications that would have excluded them from published clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=17144366238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144366238&partnerID=8YFLogxK

U2 - 10.1517/14656566.6.3.465

DO - 10.1517/14656566.6.3.465

M3 - Review article

VL - 6

SP - 465

EP - 477

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 3

ER -